: iStockAnalyst.com Symbols Feed

Indices Rally, But Give Back A Big Chunk Of Post-FOMC Gains

Thu, 13 Aug 2009 03:45:12 GMT

The indices had a volatile session, particularly in the afternoon after the FOMC made their announcement. But the day started off with a bang at the get-go, with a very strong rally that saw the Nasdaq 100 run from 1594 to 1625 inside the first 1-1 1/2 hours. The S&P 500 at that point ran from 993 to 1008. They spent the next couple hours backing and filling and consolidating, rolled over after the FOMC announcement, and then snapped back after holding secondary support sharply. It appeared there was massive short covering as the indices gapped up intraday. After another 45 minutes of consolidation, they failed to break out, and in the last 20 minutes rolled over sharply to take back a big chunk of the gains. Still, net on the day the Dow was up 120 to 9361.61, after reaching as high as 9424 and change. The S&P 500 closed at 1005.81, up 11.46, but had a 1012.78 high earlier, and the Nasdaq 100 was 15 points[More...]

Rally Rolls On

Mon, 03 Aug 2009 22:41:59 GMT

The indices had another strong start to the week with another strong gap up at the opening on very positive futures. They then backed and filled, retested early lows and then rallied steadily to mid-afternoon when they reached their peaks for the day. They pulled back into the last hour, but in the last 15-mintues snapped back sharply to close near the highs for the day on the Nasdaq 100 and not far from them on the S&P 500. Net on the day the Dow gained 114.95 to 9286.56, just 12 points off its high. The S&P 500 was up 15.15 to 1002.63, closing over 1000 for the first time since November. That was less than a point from its highs. The Nasdaq 100 advanced 24.76 to 1628.12, just pennies from its high. Advance-declines were 5 to 1 positive on New York and 2/1/2 to 1 positive on Nasdaq. Up/down volume was about 7 1/2 to 1 positive on New York on total volume of just under 1.2[More...]

FDA Calendar Updates: Former Extreme Trade Transcept Pharma (NASDAQ:TSPT) Surges On Deal

Mon, 03 Aug 2009 16:56:01 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 297 entries as of 8/3/09.. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, ANDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete (...)[More...]

Surging Markets Disregard Negative Divergences and Overbought Oscillators

Thu, 23 Jul 2009 23:29:26 GMT

The market had an extremely strong session on Thursday, and the rally rolls on. The day started out with a move up off the opening, and just accelerated from there, reaching the session highs around early afternoon. They pulled back to test the intraday moving averages successfully, and then moved back up to retest the highs, creating doubletops at 1605 NDX and just under 980 SPX. In the last half hour or so they gave back a bit of it, but still closed strong. Net on the day the Dow was up over 188 points at 9069.29, the S&P 500 up 22.22 at 976.29, and the Nasdaq 100 up 36.52 at 1601.52. Advance-declines were better than 5 to 1 positive on New York and about 3 ½ to 1 positive on Nasdaq. Up/down volume was more than 1.1 billion to the upside and 225 million to the downside, about 4 ½ to 1 positive, on New York. Nasdaq traded a heavy 3 billion shares and had an[More...]

Trendbreaking Down-Session

Tue, 23 Jun 2009 01:52:53 GMT

The indices got hammered from the get-go, and were down all morning until early afternoon when they tried to move back. But it was a rather unenthusiastic rally try, which looked corrective, and sure enough in the last 20 minutes they rolled over hard, with the S&P 500 closing at the lows for the day going away and the Dow not far from it. Net on the day the Dow was down 200.72 at 8379.01, the S&P 500 down a whopping 28.19 at 893.04, and the Nasdaq 100 down 44.62 at 1426.61. The Philadelphia Semiconductor Index (SOXX) down 9.87 or nearly 4 percent at 254.60. The technicals were horrible with advance-declines 2710 lower and 345 up, almost 7 to 1 gegative, on New York and 5 to 1 negative on Nasdaq. Up/down volume was even worse, with 1.3 billion traded to the downside and only 93 million to the upside on New York, a 14 to 1 ratio. Nasdaq had more than 2 billion to the downside and 236[More...]

Indices Give Up Half The Day's Rally To Close Mixed

Wed, 17 Jun 2009 22:32:57 GMT

The markets ended mixed after some intraday volatility. They were down in the morning, held near the 1440 area on the NDX and 904 on the S&P 500 and then bounced in a 5-wave move over the next several hours, reaching back up towards key overhead resistance at 1470 NDX and just under 920 SPX. When they failed to take that out, they rolled over and gave back about half the rally, which put the Dow and SPX back in the negative column at the close. Net on the day the Dow closed at 8497.18, down 7.49. That was about 65 points off its high. The S&P 500 fell 1.26 to 910.71, about 8 points off its high. The Nasdaq 100 still gained 12.64 today at 1455.89, but still closed 15 points off its high. The Philadelphia Semiconductor Index (SOXX) managed to gain 2.45 today, a little less than 1 percent, at 266.16. The technicals were still negative by a little better than 3 to 2 on[More...]

FDA Calendar Updates: BDSI Is Worth The Wait, Zicam Warning

Wed, 17 Jun 2009 00:36:58 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response lette (...)[More...]

Stocks Of The Day: Savient Pharmaceuticals (NASDAQ: SVNT); Ameriprise Financial (NYSE: AMP)

Mon, 15 Jun 2009 16:30:30 GMT

Savient Pharmaceuticals Inc., a specialty biopharmaceutical company, focuses on developing, manufacturing, and marketing pharmaceutical products that target unmet medical needs.[More...]

Savient (Nasdaq: SVNT) Up Big On Friday

Fri, 12 Jun 2009 20:14:15 GMT

Savient Pharmaceuticals (SVNT) is trading about 60% higher in afternoon trading on Friday, and the circumstances surrounding the massive gains a bit perplexing. Savient, a specialty biopharmaceuticals company, has a drug called Krystexxa that is used to treat gout patients. This drug has been the subject of an FDA review since December, and today the FDA released a statement saying that, although the drug does seem to work, there still may be significant health concerns associated with the treatment. The drug has not received approval and there will be an additional panel asked to study the drug at the request of the FDA. This FDA review ended in an inconclusive fashion, after already delaying its findings once, it would seem to[More...]

FDA Calendar Updates: BDSI, SVNT Deadlines Approach

Fri, 12 Jun 2009 00:55:00 GMT

Savient Pharmaceuticals Secures $60 Million in Public Offering

Fri, 16 Oct 2009 13:48:00 GMT

Savient Pharmaceuticals, a specialty biopharmaceutical company, has closed its previously announced underwritten public offering.
After underwriting discounts and commissions and estimated offering expenses, Savient received net proceeds of approximately $60.9 million.
As a result, Savient sold a total of 4.94 million shares of its common stock at a price to the public of $13.29 per share.

: iStockAnalyst.com Symbols Feed

Indices Rally, But Give Back A Big Chunk Of Post-FOMC Gains

Rally Rolls On

FDA Calendar Updates: Former Extreme Trade Transcept Pharma (NASDAQ:TSPT) Surges On Deal

Surging Markets Disregard Negative Divergences and Overbought Oscillators

Trendbreaking Down-Session

Indices Give Up Half The Day's Rally To Close Mixed

FDA Calendar Updates: BDSI Is Worth The Wait, Zicam Warning

Stocks Of The Day: Savient Pharmaceuticals (NASDAQ: SVNT); Ameriprise Financial (NYSE: AMP)

Savient (Nasdaq: SVNT) Up Big On Friday

FDA Calendar Updates: BDSI, SVNT Deadlines Approach

Savient Pharmaceuticals Secures $60 Million in Public Offering

BofA, Ford, Alcoa, Huron Consulting are big movers

FedEx, Beazer Homes, Netflix are big movers

BenchmarkJournal.Com Free Analyst Review for VPRT, ARCC, STAR, VRNM, XOMA and SVNT

Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results ; Ends First Half of 2009 With $76.6M in Cash and Short-Term Investments

Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results

Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)

Lawrence Gyenes Appointed Chief Financial Officer of Columbia Laboratories

FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout

Savient Announces Election of Dr. Ginger D. Constantine to Board of Directors

Savient to Present Multiple Abstracts At the European League Against Rheumatism (EULAR) 2009 Annual Congress

Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout

Savient Pharmaceuticals Reports First Quarter 2009 Financial Results

Form 4 Gionco David For: Feb 27 (10K)

Form 4 Hamelin Paul For: Sep 11 (10K)

Form 4 YACHMETZ PHILIP K For: Sep 14 (10K)

Form 3 Constantine Ginger For: Jun 05 (10K)

Form 4 SAVIENT PHARMACEUTICALS For: May 26 Filed by: Hamelin Paul (10K)

Form 4 JAEGER STEPHEN O For: May 05 (10K)

Form 4 THOMPSON VIRGIL For: May 05 (10K)

Form 4 HELLER ALAN L For: May 05 (10K)

Form 4 KLEIN JOSEPH III For: May 05 (10K)

Form 4 Simon Lee S For: May 05 (10K)